Search results for "Eryt"

showing 10 items of 966 documents

A Highly Decreased Binding of Cyclic Adenosine Monophosphate to Protein Kinase A in Erythrocyte Membranes is Specific for Active Psoriasis

2002

A cyclic adenosine monophosphate binding abnormality in psoriatic erythrocytes that could be corrected by retinoid treatment has been reported. It was tested whether this binding abnormality is specific for psoriasis and the effects of treatment were compared with etretinate, cyclosporine A, or anthralin on 2-(3)H-8-N(3)-cyclic adenosine monophosphate binding to the regulatory subunit of protein kinase A in erythrocyte membranes. One hundred and fifteen individuals were evaluated, including: (i) 34 healthy persons; (ii) 15 patients with nonatopic inflammatory skin diseases (eczema, erythroderma, tinea, Grover's disease, erysipelas, urticaria); (iii) eight with other dermatoses mediated by i…

AdultMaleAzidesmedicine.medical_specialtyAdolescentmedicine.drug_classAdministration TopicalAnti-Inflammatory AgentsErythrodermaEtretinateDermatologySeverity of Illness IndexBiochemistryRetinoidschemistry.chemical_compoundPsoriasis Area and Severity IndexKeratolytic AgentsPsoriasis Area and Severity IndexPsoriasisInternal medicineCyclic AMPmedicineHumansPsoriasisCyclic adenosine monophosphateRetinoidMolecular BiologydermatitisAgedErythema nodosumbusiness.industryErythrocyte MembraneAffinity LabelsCell BiologyAtopic dermatitisAnthralinMiddle Agedmedicine.diseaseCyclic AMP-Dependent Protein KinasesEndocrinologychemistryEtretinateCyclosporineFemaleDermatologic Agentsbusinesscyclosporine AProtein Bindingmedicine.drugJournal of Investigative Dermatology
researchProduct

Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflam…

2010

AbstractTo identify the genetic basis of circulating concentrations of monocyte chemoattractant protein-1 (MCP-1), we conducted genome-wide association analyses for MCP-1 in 3 independent cohorts (n = 9598). The strongest association was for serum MCP-1 with a nonsynonymous polymorphism, rs12075 (Asp42Gly) in DARC, the gene for Duffy antigen receptor for chemokines, a known vascular reservoir of proinflammatory cytokines (minor allele frequency, 45.6%; P < 1.0 * 10−323). This association was supported by family-based genetic linkage at a locus encompassing the DARC gene (genome-wide P = 8.0 * 10−13). Asp42Gly accounted for approximately 20% of the variability in serum MCP-1 concentration…

AdultMaleCCR2ChemokineErythrocytesImmunologyReceptors Cell SurfacePolymorphism Single NucleotideBiochemistryProinflammatory cytokineCohort StudiesmedicineHumansCytokine bindingReceptorInterleukin 6Chemokine CCL2biologyMonocyteCell BiologyHematologyMiddle AgedMolecular biologymedicine.anatomical_structureChromosomes Human Pair 1Genetic LociImmunologybiology.proteinFemaleInterleukin 18Inflammation MediatorsDuffy Blood-Group SystemGenome-Wide Association StudyBlood
researchProduct

Prospective, blinded comparison of cytology and DNA-image cytometry of brush biopsies for early detection of oral malignancy

2012

summary Objectives: Adjunctive techniques like DNA image cytometry (DNA-ICM) have been attributed to enhance the diagnostic performance of oral brush biopsies. The aim of the study was an evaluation of brush biopsies, analysed according to morphological criteria and by DNA-ICM vs. histological findings in a blinded prospective trial. Materials and methods: Eighty eight brush biopsies of 70 patients were sampled. Only clinical suspicious but not evident malignant oral lesions were included. Clinical diagnosis was leukoplakia (n = 36), lichen planus (n = 18), verruciform erythroplakia (n = 12), erythroleukoplakia (n = 9), erosion (n = 7) and induration (n = 6). Evaluation was conducted via hi…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyCytodiagnosisMalignancySensitivity and SpecificityCytologyOral and maxillofacial pathologyImage Processing Computer-AssistedmedicineCarcinomaHumansSingle-Blind MethodProspective StudiesFalse Negative ReactionsMouth FloorEarly Detection of CancerAgedImage CytometryLeukoplakiaAged 80 and overErythroplakiaPloidiesbusiness.industryMouth MucosaHistologyDNA NeoplasmMiddle Agedmedicine.diseaseTongue Neoplasmsstomatognathic diseasesOncologyDysplasiaErythroplasiaCarcinoma Squamous CellFemaleMouth NeoplasmsLeukoplakia OralOral SurgerybusinessPrecancerous ConditionsCarcinoma in SituLichen Planus OralOral Oncology
researchProduct

Efficacy of mometasone furoate microemulsion in the treatment of erosive-ulcerative oral lichen planus: pilot study

2004

Background:  Oral lichen planus (OLP) is a frequent immunological chronic disease, having different clinical forms: asymptomatic and symptomatic. Symptomatic OLP has been palliated with topical corticosteroids with different levels of efficacy and safety. The purpose of this pilot phase II clinical trial was to determine the efficacy of mometasone furoate microemulsion upon the symptoms and signs of erosive-ulcerative OLP. Methods:  Forty-nine patients with clinical and histologically confirmed erosive-ulcerative OLP were enrolled in this study (36 women and 13 men). Their average age was 56.4 years (from 28 to 78). The treatment consisted of 0.1% mometasone furoate microemulsion mouthwash …

AdultMaleCancer Researchmedicine.medical_specialtyErythemamedicine.drug_classAdministration TopicalAnti-Inflammatory AgentsMouthwashesMometasone furoatePilot ProjectsAsymptomaticPathology and Forensic Medicinestomatognathic systemHumansMedicineAdverse effectGlucocorticoidsPregnadienediolsAgedbusiness.industryMometasoneMiddle Agedmedicine.diseaseDermatologyClinical trialstomatognathic diseasesOtorhinolaryngologyPeriodonticsCorticosteroidEmulsionsFemaleOral lichen planusOral Surgerymedicine.symptombusinessMometasone FuroateLichen Planus Oralmedicine.drugJournal of Oral Pathology and Medicine
researchProduct

Biologic relevance of elevated red cell adenosine deaminase activity in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria.

1992

Red cell adenosine deaminase (ADA-RBC) activity in patients with myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria is significantly increased compared to that observed in normal controls. ADA-RBC activity is not related to fetal hemoglobin concentration, but it is significantly correlated with hemoglobin concentration at diagnosis and with the degree of morphologic dysplasia in the erythroid lineage. The results of our study suggest that the observed enzymatic abnormality may constitute a non-specific manifestation of the stem cell alteration that determines these disorders.

AdultMaleCancer Researchmedicine.medical_specialtyErythrocytesAdenosine DeaminaseHemoglobinuria Paroxysmal030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineAdenosine deaminaseInternal medicineFetal hemoglobinmedicineHumansPreleukemiaAgedRed Cellbiologybusiness.industryMyelodysplastic syndromeshemic and immune systemsGeneral MedicineMiddle Agedmedicine.diseaseEndocrinologyOncologyDysplasia030220 oncology & carcinogenesisMyelodysplastic Syndromesbiology.proteinParoxysmal nocturnal hemoglobinuriaElevated red cell adenosine deaminase activityFemaleHemoglobinbusinessTumori
researchProduct

Stereotactic fractionated radiotherapy in patients with optic nerve sheath meningioma.

2002

Abstract Purpose: To evaluate the effectiveness of stereotactic fractionated radiotherapy (SFRT) in the treatment of optic nerve sheath meningioma (ONSM). Methods and Materials: Between 1994 and 2000, a total of 39 patients with either primary ( n = 15) or secondary ( n = 24) ONSM were treated with SFRT and received a median total tumor dose of 54 Gy using 1.8 Gy/fraction. Results: The radiographic response to SFRT was documented in all patients as stable disease (no change) except for 1 patient with a partial response. After a median follow-up of 35.5 months, all patients with ONSM were alive without recurrence. The visual fields and visual acuity were improved in 6 of 15 and 1 of 16 exami…

AdultMaleCancer Researchmedicine.medical_specialtyVisual acuityTime FactorsFractionated radiotherapyErythemaAdolescentRadiographyRadiosurgerymedicineHumansRadiology Nuclear Medicine and imagingIn patientAge of OnsetAgedAged 80 and overRadiationbusiness.industryStandard treatmentOptic Nerve NeoplasmsDose fractionationMiddle Agedmedicine.diseaseSurgeryOptic nerve sheath meningiomaTreatment OutcomeOncologyDisease ProgressionFemaleRadiologyDose Fractionation Radiationmedicine.symptombusinessMeningiomaFollow-Up StudiesInternational journal of radiation oncology, biology, physics
researchProduct

Effect of ouabain and furosemide on erythrocyte sodium and phosphate transport.

1981

The effects of ouabain and furosemide on the unidirectional efflux of sodium and phosphate ions were studied in freshly drawn human red blood cells (RBCs). In the presence of physiologic concentrations of sodium and potassium the rate of sodium efflux was reduced by 74% due to ouabain sensitivity. Furosemide (1.0 mmol/l) reduced ouabain-insensitive sodium transport rate by a further 50%. Thus, 13% of total sodium efflux was inhibited by furosemide when ouabain was present. In the absence of ouabain, however, furosemide inhibited 31% of total sodium transport, indicating that it also affected ouabain-sensitive sodium efflux. Phosphate transfer of RBCs was almost 1.0 mmol/l RBCs per hour. Ery…

AdultMaleCell Membrane PermeabilityErythrocytesPotassiumSodiumchemistry.chemical_elementBiological Transport ActiveOuabainIon ChannelsPhosphateschemistry.chemical_compoundHydrolysisFurosemidemedicineHumansPharmacology (medical)OuabainPharmacologyChromatographyChemistrySodiumFurosemidePhosphateBiochemistryPotassiumEffluxSodium-Potassium-Exchanging ATPaseAdenosine triphosphatemedicine.drugClinical pharmacology and therapeutics
researchProduct

Red cell enzyme polymorphisms in Bulgaria.

1972

7 human red cell enzyme polymophisms have been typed on a sample of n=138 unrelated adults from Bulgaria, which revealed the following gene frequencies: ADA1=0.8623. ADA2=0.1376; AK1=0.9637, AK2=0.0362; 6-PGDA=0.9891, 6-PGDC=0.0108; PGM11=0.8346, PGM12=0.1653; PA=0.1596, PB=0.7983, PC=0.0420. In the LDH-system one B-subunit variant was found, whilst no Peptidase A or B variant could be observed. The anthropological significance of these findings is discussed.

AdultMaleErythrocytesAcid PhosphataseElectrophoresis Starch GelBiologyGene FrequencyAminohydrolasesGeneticsHumansBulgariaGeneMolecular BiologyGenetics (clinical)GeneticsPolymorphism GeneticL-Lactate DehydrogenasePhosphogluconate DehydrogenasePhosphotransferasesBlood Protein ElectrophoresisMolecular medicineHuman geneticsAK2Red cell enzymeEnzymesGenetics PopulationPhosphoglucomutaseFemalePeptide HydrolasesHumangenetik
researchProduct

Reduction in blood viscosity at low rates of shear by surface active substances: a new hemorheologic phenomenon

1968

AdultMaleErythrocytesMaterials scienceAdolescentPhysiologyBlood viscosityOleic AcidsBlood SedimentationBlood ViscositySurface-Active AgentsShear (geology)Physiology (medical)HumansFemaleComposite materialRheologyBiorheology
researchProduct

Fumaric acid ester treatment in cutaneous lupus erythematosus (CLE): a prospective, open-label, phase II pilot study.

2016

Objective The aim of the study was to assess the efficacy and safety of fumaric acid esters (FAEs) in patients with cutaneous lupus erythematosus (CLE). Methods In this 24-week, prospective, open-label, phase II pilot study, 11 patients with CLE, refractory to topical corticosteroids, were included. The primary endpoint of the study was the evaluation of the efficacy of FAEs after 24 weeks of treatment as assessed by the Revised Cutaneous Lupus Disease Area and Severity Index (RCLASI). Results Compared to baseline, significant improvement in the mean total RCLASI activity score and the mean RCLASI activity score for skin lesions was observed in week 12 ( p = 0.002, p = 0.002, respectively) …

AdultMaleFumaric acidmedicine.medical_specialtyColicPilot ProjectsSeverity of Illness IndexDrug Administration Schedule030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRheumatologyFumaratesLupus Erythematosus CutaneousMedicineHumansIn patientProspective Studies030203 arthritis & rheumatologybusiness.industryHeadacheMiddle AgedDermatologyAlternative treatmentClinical trialTreatment OutcomeFumaric Acid EsterschemistryCutaneous Lupus ErythematosusFemaleOpen labelbusinessLupus
researchProduct